Continuing Education Activity

Quinapril is an angiotensin-converting enzyme inhibitor (ACEi) developed in the 1980s. Quinapril is a medication utilized to manage hypertension, a significant risk factor for coronary heart disease. In addition, quinapril is used off-labeled for managing chronic heart failure (CHF), slowing the progression of renal disease in patients with diabetes. Quinapril is a non-sulfhydryl ACEi that blocks the action of angiotensin-converting enzyme (ACE), which plays a vital role in the renin-angiotensin-aldosterone system (RAAS). Quinapril has effectively lowered systolic blood pressure by 13 mm Hg and diastolic blood pressure by 10 mm Hg in approximately 2 out of 3 individuals. As is true for most drugs in this class, the medication regimen may be increased or decreased depending on patient response.

This activity reviews the indications, mechanism of action, administration, adverse events, contraindications, monitoring, and toxicity of quinapril. In addition, this article highlights pertinent points regarding quinapril as needed by interprofessional teams managing patients with hypertension and other cardiovascular co-morbidities.

Objectives:

• Identify the FDA and non-FDA-approved indications for quinapril therapy based on the patient's cardiovascular condition and risk factors.
• Screen patients for contraindications or potential drug interactions before initiating quinapril therapy.
• Apply knowledge of quinapril's adverse effects and potential complications to monitor patients for any signs of drug-related adverse events.
• Collaborate with other healthcare professionals, such as cardiologists and pharmacists, to optimize the use of quinapril to manage hypertension and cardiovascular conditions.

Indications

Quinapril is an angiotensin-converting enzyme (ACE) inhibitor developed in the 1980s. Researchers determined that quinapril had a lower incidence of adverse events than other ACE inhibitors (ACEi) like captopril and enalapril, as well as the thiazide diuretic chlorthalidone.[1] Quinapril has effectively lowered systolic blood pressure by 13 mm Hg and diastolic blood pressure by 10 mm Hg in approximately 2 out of 3 individuals.[2][3][4]

FDA-Approved Indications

• The FDA approved quinapril for the treatment of hypertension in 1989.[1]

• Quinapril is indicated in managing heart failure as an adjunctive therapy when added to conventional treatment, which can include diuretics and/or digitalis.[5] According to 2022 AHA/ACC/HFSA guidelines, quinapril is suggested for heart failure with reduced ejection fraction (HFrEF). ACEi are the cornerstone of goal-directed medical therapy (GDMT).[6]

As a class, ACEi has reduced proteinuria in diabetic patients. More importantly, research has demonstrated that quinapril reduces microalbuminuria in essential hypertension and diabetic patients without significantly affecting insulin effectiveness or lipid levels.[7] 

Mechanism of Action

Quinapril is a non-sulfhydryl ACEi that blocks the action of ACE, which plays a vital role in the renin-angiotensin-aldosterone system (RAAS). Quinapril is metabolized to quinaprilat in the liver, where the drug enters circulation. After conversion, the liver releases quinaprilat into the peripheral circulation, inhibiting ACE; the enzyme converts angiotensin I to angiotensin II. Angiotensin II is the hormone that stimulates the hormone aldosterone, which is responsible for salt and water retention.[8] 

A combination of salt and water retention and peripheral vasculature constriction leads to systemic hypertension. Quinapril (and its metabolite quinaprilat) decreases systemic (peripheral and renal) vascular resistance, thereby decreasing blood pressure. The renal system clears the majority of quinapril, and ACEi maximum observable effect occurs at 5 hours.[4][9] The results of a study demonstrated that long-term treatment with quinapril improves impaired endothelial dysfunction in patients with atherosclerotic risk factors.[10] In addition, quinapril improves coronary microvascular dysfunction and coronary flow reserve.[11]

Pharmacokinetics

Absorption: The time for peak plasma concentration is within 1 hour. The extent of absorption is approximately 60% (based on quinapril and its metabolites).

Distribution: Quinalapril has plasma protein binding of 97%. Distribution is widespread, except for brain tissue.[12]

Metabolism: Quinapril is converted to its active metabolite quinaprilat. Quinaprilat has a short elimination half-life but dissociates from ACE slowly, allowing once or twice daily administration.

Excretion: Quinapril and its metabolites are excreted by the kidney.[13]

Administration

Quinapril is administered via the oral route. The drug is available in 5, 10, 20, and 40 mg tablets—plasma clearance of quinapril correlates to a patient's creatinine clearance. The dosing range that researchers tested was between 0.625 to 80 mg orally daily, but the most effective antihypertensive effects were noted at doses of 20 mg orally daily.[3] Quinapril is also available in fixed-dose combination with hydrochlorothiazide for the management of hypertension.

Hypertension: Dosage 10 to 80 mg by mouth daily. Patients with mild to moderate hypertension should be initiated on a dosage between 5 and 20 mg orally daily, with a dose increase every 2 weeks, if needed. The dosage should be reduced to 2.5 to 20 mg orally daily in patients with renal impairment.[14] Interestingly, twice daily dosing achieves a more significant blood pressure trough effect in hypertensive patients than an equivalent total daily dose. Quinapril and hydrochlorothiazide is administered as 20 mg/12.5 mg fixed dose combination.

Chronic Heart Failure With Reduced Ejection Fraction (HFrEF): Patients with HFrEF are started on a lower dosage of 5 mg twice daily. According to the 2022 AHA/ACC/HFSA heart failure guideline, the target dosage is 20 mg twice daily. The undesirable adverse effects precipitate (hypotension, orthostasis, or azotemia) may require dose reduction.[15]

Specific Patient Population 

Hepatic impairment: The manufacturer package insert has no dose adjustment guidance for patients with hepatic impairment. 

Renal impairment: The apparent elimination half-life of quinaprilat, the active metabolite of quinapril, increases as creatinine clearance (CrCl) decreases. Therefore, the dose should be adjusted based on creatinine clearance. Recommended maximum initial doses are as follows:

• 10 mg if creatinine clearance is more than 60 mL/min

• 5 mg if creatinine clearance is 30 to 60 mL/min

• 2.5 mg if creatinine clearance is 10 to 30 mL/min

• No sufficient dose recommendation data is available when creatinine clearance is below 10 mL/min.

• For hemodialysis or peritoneal dialysis patients, start quinapril at 2.5 mg daily; no supplement is necessary following dialysis.

Pregnancy considerations: Quinapril is considered a former FDA pregnancy category D medicine. Per the manufacturer box warning, discontinuation of quinapril is recommended as soon as pregnancy is detected. Quinapril can cross the placenta, and exposure to ACEi during the first trimester may increase the risk of fetal malformations.[16] According to ACOG, ACEi, including quinapril, is contraindicated in pregnancy as it increases the risk of malformations like renal dysgenesis and fetal growth restriction.[17]

Breastfeeding considerations: The manufacturer advises caution for quinapril therapy in nursing mothers as the drug is present in breast milk.[18]

Pediatric patients: Limited data is available for using quinapril in pediatric patients, although it can be used off-label for hypertension in children aged 6 and older. 

Older patients: The manufacturer recommends a 10 mg daily dosage followed by titration as the initial dosage of quinapril in older patients.

Adverse Effects

Adverse effects of quinapril include dry cough (as is typical among all ACEi class members), hyperkalemia, angioedema, dizziness, hypotension, and renal dysfunction.[19][20][21] Less common adverse effects include skin rash and dysgeusia.[21] Angioedema is a rare but well-documented adverse effect of ACEi, which often presents as facial, tongue, and lip swelling. However, unique instances present with isolated swelling of the small bowel. This presentation, also called intestinal-type angioedema, may manifest in patients taking ACEi presenting with abdominal pain, nausea, vomiting, and diarrhea.[22] Although one report of agranulocytosis is available in a neutropenic patient using quinapril, no other reports of agranulocytosis were noted in the literature, as found in rare cases of captopril use, one of the original ACE inhibitors.

Drug-Drug Interactions

• Diuretic agents: Coadministration of quinapril with other diuretics may occasionally reduce blood pressure after initiating therapy. To minimize the hypotensive effects, either discontinue the diuretic or cautiously increase the salt intake before starting quinapril therapy. The reduced initial dose of quinapril may be used for patients where discontinuing the diuretic is not feasible.

• Agents increasing serum potassium: Coadministration of quinapril with other agents that raise the level of serum potassium may lead to hyperkalemia. Therefore, monitoring the serum potassium level in such patients is recommended.

• Tetracycline and other agents that interact with magnesium: Coadministration of quinapril with tetracycline may reduce tetracycline absorption by 28% to 37% due to the high magnesium content in quinapril tablets. 

• Lithium: Coadministration of quinapril with lithium may increase serum lithium levels, leading to lithium toxicity symptoms.

• Gold: Coadministration of quinapril with injectable gold may lead to nitritoid reactions, which lead to symptoms like facial flushing, nausea, vomiting, and hypotension.

• Non-steroidal anti-inflammatory agents, including selective cyclooxygenase-2 inhibitors: Coadministration of quinapril with NSAIDs or selective COX-2 inhibitors in older patients may result in deterioration of renal function or acute renal failure. 

• Agents that inhibit mTOR: Coadministration of quinapril with an mTOR inhibitor (eg, temsirolimus) may increase the risk for angioedema.

FDA Safety Alert: In December 2022, quinapril (4 batches) was withdrawn from the market in a voluntary nationwide recall due to nitrosamine impurity. Nitrosamine is a potential carcinogen; in consequence, clinicians should remain cautious while prescribing.[23]

Contraindications

ACE inhibitors (ACEi), including quinapril, are contraindicated in pregnancy since they counteract RAAS, which is essential for fetal renal development.[21] Possible complications of using quinapril in pregnancy may include but are not limited to fetal lung hypoplasia, fetal renal hypoplasia/failure, oligohydramnios, skeletal hypoplasia, hypotension, and death. Quinapril is also contraindicated in patients with hyperkalemia, current angioedema (regardless of the ACEi), bilateral renal artery stenosis, acute kidney injury leading to renal failure with prior ACEi use, and aliskiren use within the last 36 hours. The use of quinapril is contraindicated in patients taking neprilysin inhibitors (ARNI) such as sacubitril due to the increased risk of angioedema. A period of 36 hours is recommended before switching to or from sacubitril/valsartan and quinapril.[24]

Monitoring

Following the initial dose of quinapril, the patient should be kept under medical observation for at least 2 hours for hypotension or orthostasis. If present, they should remain under observation until blood pressure normalizes. For each dose increase, similar medical care should be provided to patients to avoid the risk of adverse effects.[22] The most serious adverse effects requiring monitoring are angioedema and hyperkalemia. Clinicians need to inform patients about potential facial, tongue, and lip swelling so that they can monitor for angioedema. Patients and clinicians must also be cognizant of abdominal symptoms like abdominal pain, nausea, vomiting, and diarrhea, which may suggest intestinal-type angioedema.[22] 

Routine laboratory assessment should be performed, including a basic metabolic panel to monitor serum potassium levels and renal function. The current recommendation is to monitor serum electrolytes and renal function 2 to 3 weeks after initiation and at every dose titration. In addition, patients should receive instruction to avoid high-potassium foods (ie, alternative salt in hypertension, bananas, avocados) and be advised against concurrent use of other agents that contribute to hyperkalemia (ie, aldosterone antagonists). Patients who take many antihypertensive agents also need to be cautious, as quinapril may contribute to significant hypotension, especially following the administration of the first dose. 

Occasional or rare monitoring of liver function tests and complete blood counts may be warranted in quinapril as rare adverse effects such as agranulocytosis and hepatic enzyme elevation may occur.[19] If patients report a persistent, dry cough while taking quinapril, the clinician may consider a therapeutic switch to an angiotensin receptor-blocking agent (ARB). According to Primary Prevention of Cardiovascular Disease guidelines by ACC/AHA, the atherosclerotic cardiovascular disease (ASCVD) risk estimator plus should be used to guide treatment decisions. For patients with hypertension, comprehensive lifestyle interventions are suggested. The goal blood pressure is <130/80mm Hg.[25] Volume status, weight, and vitals should be monitored each visit for patients with heart failure on quinapril therapy. Hemodynamic status should be monitored during acute decompensation by assessment of perfusion and congestion.  Assessment of patient-reported health status using a standardized questionnaire like the Kansas City Cardiomyopathy Questionnaire (KCCQ) or the Minnesota Living with Heart Failure questionnaire is useful as it provides information regarding the patient's overall functional status and quality of life.[6][26]

Toxicity

Overdosing ACEi may lead to significant hypotension, renal failure, hyperkalemia, and hyponatremia.[19][20][21] After ingesting 20 times the daily amount, significant hypotension occurred within the first 6 hours of ingestion. Clinicians could consider activated charcoal if a patient presents within an hour of ingestion.[27] To date, no true antidote for quinapril is available.

Per the manufacturer, hemodialysis and peritoneal dialysis may only significantly eliminate quinapril and its metabolite. Angiotensin II can be used as a specific antidote in instances of a quinapril overdose. However, angiotensin II is only available in research facilities. Since quinapril causes hypotension through vasodilation and effective hypovolemia, the infusion of the normal saline solution may be helpful when treating quinapril overdose. Insertion of the central line and administration of norepinephrine may be required in refractory hypotension.[28]

Enhancing Healthcare Team Outcomes

Since quinapril joined the market, it has been an effective medication for treating hypertension and chronic heart failure. Key points to remember are that 1) average systolic blood pressure change is approximately 13 mm Hg while average diastolic blood pressure change is approximately 10 mm Hg with maximum effect at 5 hours, and 2) patients require close monitoring for adverse effects such as hyperkalemia, renal dysfunction, and angioedema.

Clinicians should determine the dose of quinapril based on the patient's clinical diagnosis and other medical conditions. Nursing staff must monitor vitals, verify the dose before administering the drug, and consult with the prescriber about their concerns and recommendations. Pharmacists must perform medication reconciliation and counsel patients on the safe use of the drug. During hypertensive urgency and emergency, clinicians should rapidly stabilize the patient. Medical toxicologist consultation may be required in complex overdose. If the overdose is intentional, a psychiatrist consultation is necessary. All interprofessional healthcare team members must communicate openly with each other to ensure optimal patient treatment and outcomes. Prescribing, administering, and monitoring quinapril requires the coordinated effort of an interprofessional healthcare team. According to AHA/ACC/HFSA 2022 guidelines, multiple clinical trials have shown that patient care provided by an interprofessional team improves outcomes related to hypertension and heart failure therapy.[6]

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Frank GJ, Knapp LE, McLain RW. Overall tolerance and safety of quinapril in clinical trials. Angiology. 1989 Apr;40(4 Pt 2):405-15. [PubMed: 2650583]

2.

Sedman AJ, Posvar E. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure. Angiology. 1989 Apr;40(4 Pt 2):360-9. [PubMed: 2539762]

3.

Maclean D. Quinapril: a double-blind, placebo-controlled trial in essential hypertension. Angiology. 1989 Apr;40(4 Pt 2):370-81. [PubMed: 2650581]

4.

Begg EJ, Robson RA, Bailey RR, Lynn KL, Frank GJ, Olson SC. The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment. Br J Clin Pharmacol. 1990 Aug;30(2):213-20. [PMC free article: PMC1368220] [PubMed: 2144994]

5.

Drugs for chronic heart failure. Med Lett Drugs Ther. 2021 Jun 14;63(1626):89-96. [PubMed: 34181628]

6.

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 May 03;79(17):e263-e421. [PubMed: 35379503]

7.

Dominguez LJ, Barbagallo M, Kattah W, Garcia D, Sowers JR. Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects. Am J Hypertens. 1995 Aug;8(8):808-14. [PubMed: 7576397]

8.

Raia JJ, Barone JA, Byerly WG, Lacy CR. Angiotensin-converting enzyme inhibitors: a comparative review. DICP. 1990 May;24(5):506-25. [PubMed: 2188439]

9.

Squire IB, Macfadyen RJ, Lees KR, Hillis WS, Reid JL. Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure. Br J Clin Pharmacol. 1994 Aug;38(2):117-23. [PMC free article: PMC1364856] [PubMed: 7981011]

10.

Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol. 2000 Jan;35(1):60-6. [PubMed: 10636260]

11.

Marinescu MA, Löffler AI, Ouellette M, Smith L, Kramer CM, Bourque JM. Coronary microvascular dysfunction, microvascular angina, and treatment strategies. JACC Cardiovasc Imaging. 2015 Feb;8(2):210-20. [PMC free article: PMC4384521] [PubMed: 25677893]

12.

Kaplan HR, Taylor DG, Olson SC, Andrews LK. Quinapril--a preclinical review of the pharmacology, pharmacokinetics, and toxicology. Angiology. 1989 Apr;40(4 Pt 2):335-50. [PubMed: 2539761]

13.

Kieback AG, Felix SB, Reffelmann T. Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1337-47. [PubMed: 19761414]

14.

Miller MA, Texter M, Gmerek A, Robbins J, Shurzinske L, Canter D. Quinapril hydrochloride effects on renal function in patients with renal dysfunction and hypertension: a drug-withdrawal study. Cardiovasc Drugs Ther. 1994 Apr;8(2):271-5. [PubMed: 7918140]

15.

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 May 03;79(17):1757-1780. [PubMed: 35379504]

16.

Pucci M, Sarween N, Knox E, Lipkin G, Martin U. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits. Expert Rev Clin Pharmacol. 2015 Mar;8(2):221-31. [PubMed: 25612630]

17.

American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol. 2019 Jan;133(1):e26-e50. [PubMed: 30575676]

18.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Feb 28, 2019. Quinapril. [PubMed: 30000147]

19.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Feb 11, 2018. Quinapril. [PubMed: 31643770]

20.

Canter D, Frank GJ, Knapp LE, McLain RW. The safety profile of quinapril: is there a difference among ACE inhibitors? Clin Cardiol. 1990 Jun;13(6 Suppl 7):VII39-42. [PubMed: 2189620]

21.

Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitors. Ann Pharmacother. 1996 Jan;30(1):55-61. [PubMed: 8773167]

22.

Palmquist S, Mathews B. Isolated intestinal type angioedema due to ACE-inhibitor therapy. Clin Case Rep. 2017 May;5(5):707-710. [PMC free article: PMC5412761] [PubMed: 28469880]

23.

Bharate SS. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities. J Med Chem. 2021 Mar 25;64(6):2923-2936. [PubMed: 33706513]

24.

Hubers SA, Brown NJ. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation. 2016 Mar 15;133(11):1115-24. [PMC free article: PMC4800749] [PubMed: 26976916]

25.

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC, Virani SS, Williams KA, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Sep 10;74(10):e177-e232. [PubMed: 30894318]

26.

Stubblefield WB, Jenkins CA, Liu D, Storrow AB, Spertus JA, Pang PS, Levy PD, Butler J, Chang AM, Char D, Diercks DB, Fermann GJ, Han JH, Hiestand BC, Hogan CJ, Khan Y, Lee S, Lindenfeld JM, McNaughton CD, Miller K, Peacock WF, Schrock JW, Self WH, Singer AJ, Sterling SA, Collins SP. Improvement in Kansas City Cardiomyopathy Questionnaire Scores After a Self-Care Intervention in Patients With Acute Heart Failure Discharged From the Emergency Department. Circ Cardiovasc Qual Outcomes. 2021 Oct;14(10):e007956. [PMC free article: PMC8628372] [PubMed: 34555929]

27.

Lucas C, Christie GA, Waring WS. Rapid onset of haemodynamic effects after angiotensin converting enzyme-inhibitor overdose: implications for initial patient triage. Emerg Med J. 2006 Nov;23(11):854-7. [PMC free article: PMC2464381] [PubMed: 17057137]

28.

Van Reet B, Dens J. Auto-intoxication with flecainide and quinapril: ECG-changes, symptoms and treatment. Acta Cardiol. 2006 Dec;61(6):669-72. [PubMed: 17205927]

Disclosure: Nitin Tandan declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies.